Application of N-Glycan MALDI MS Imaging to Identify Cancer Biomarker Signatures in FFPE Tissues and Biofluids

Richard R Drake (1,2), Danielle Scott (1), Alyson Black (1), Connor West (1), Fred David (1), Anand Mehta (1,2), Peggi Angel (1,2)
(1) Medical University of South Carolina, Charleston, SC (2) GlycoPath, LLC, Mt. Pleasant, SC

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Richard Drake (Presenter) Medical University of South Carolina

Presenter Bio: Dr. Drake is a Professor in the Department of Cell and Molecular Pharmacology and Experimental Therapeutics at the Medical University of South Carolina and SmartState Endowed Chair in Proteomics. He is also Director of the MUSC Proteomics Center, a mass spectrometry-centric facility with state-of-the-art resources for imaging mass spectrometry, glycobiology and protein PTM applications. He is an experienced protein biochemist and glycobiologist, with particular expertise in MS imaging of tumor tissues and biomarker discovery from clinical fluids. Current efforts are in the large scale application of N-glycan MS imaging methods developed in his laboratory to liver, prostate and breast tumors. Method development of MS imaging approaches for biofluids, cells, and other types of cellular glycan classes are ongoing, as well as other extracellular matrix targeted assays.

Relevant Financial Disclosures (within past 24 months) Committee/Board/Advisory Board Bruker Daltonics SCiLS Lab Salary Bruker Daltonics Discussing Products? YES, presenter will present educational content related to products/services of one or more ineligible company(ies) listed above. Conflict mitigation IN PROCESS.

Alterations in cell surface glycosylation during tumorigenesis are well documented, and most current FDA approved cancer biomarkers are glycoproteins or glycan antigens. A MALDI mass spectrometry imaging method to spatially profile N-linked glycans in formalin-fixed paraffin-embedded (FFPE) tissue sections and tissue microarrays (TMAs) has been applied to several thousand patient samples of liver, breast and prostate cancer tissues. Analysis was done using MALDI-FTICR MS and a new rapid MALDI-TOF MS TissueTyper. The workflow has also been adapted to rapidly evaluate biofluids and cells. Structural classes of N-glycans that distinguish tumor from non-tumor for each cancer type will be described. The goals are to develop the approaches as prognostic assays for disease stratification at the time of diagnosis.